Trial Profile

Multicenter randomized crossover study about Every Second Day administration of Vonoprazan for the maintenance treatment of erosive GERD

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 05 Apr 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Vonoprazan (Primary) ; Lansoprazole
Indications Gastro-oesophageal reflux
Focus Therapeutic Use

Most Recent Events

01 Mar 2022 Results usefulness and superiority of vonoprazan assessing usefulness and superiority of vonoprazan administered every second day over PPIs in the maintenance therapy of erosive GERD, published in the Journal of Gastroenterology
30 Dec 2018 Status changed from not yet recruiting to active, no longer recruiting.
22 Dec 2017 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com